NeoGenomics, Inc. (NASDAQ:NEO) Insider George Cardoza Sells 169,230 Shares
NASDAQ:NEO opened at $40.90 on Friday. The company has a debt-to-equity ratio of 0.63, a current ratio of 13.91 and a quick ratio of 13.60. The stock has a market cap of $4.82 billion, a PE ratio of 802.20 and a beta of 0.69. The business’s 50 day moving average is $44.50. NeoGenomics, Inc. has a fifty-two week low of $25.67 and a fifty-two week high of $61.57.
NeoGenomics (NASDAQ:NEO) last posted its quarterly earnings data on Wednesday, May 5th. The medical research company reported ($0.04) earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.01 by ($0.05). The company had revenue of $115.30 million for the quarter, compared to analysts’ expectations of $112.17 million. NeoGenomics had a positive return on equity of 0.83% and a negative net margin of 2.42%. The business’s revenue for the quarter was up 8.8% on a year-over-year basis. During the same period in the previous year, the business posted ($0.07) EPS. On average, equities analysts predict that NeoGenomics, Inc. will post -0.33 earnings per share for the current year.
Institutional investors have recently added to or reduced their stakes in the business. Rhumbline Advisers lifted its holdings in NeoGenomics by 4.4% during the 1st quarter. Rhumbline Advisers now owns 314,122 shares of the medical research company’s stock worth $15,150,000 after buying an additional 13,179 shares in the last quarter. Compagnie Lombard Odier SCmA acquired a new stake in NeoGenomics during the 1st quarter worth approximately $17,411,000. Yorktown Management & Research Co Inc lifted its holdings in NeoGenomics by 14.9% during the 1st quarter. Yorktown Management & Research Co Inc now owns 23,900 shares of the medical research company’s stock worth $1,153,000 after buying an additional 3,100 shares in the last quarter. Profund Advisors LLC lifted its holdings in NeoGenomics by 41.9% during the 4th quarter. Profund Advisors LLC now owns 12,906 shares of the medical research company’s stock worth $695,000 after buying an additional 3,810 shares in the last quarter. Finally, LPL Financial LLC lifted its holdings in NeoGenomics by 15.6% during the 4th quarter. LPL Financial LLC now owns 41,624 shares of the medical research company’s stock worth $2,241,000 after buying an additional 5,611 shares in the last quarter. Institutional investors own 90.82% of the company’s stock.
Several research analysts recently weighed in on NEO shares. Zacks Investment Research downgraded shares of NeoGenomics from a “hold” rating to a “sell” rating in a research report on Wednesday, April 28th. The Goldman Sachs Group started coverage on shares of NeoGenomics in a research report on Thursday. They set a “buy” rating and a $55.00 price target for the company. Needham & Company LLC restated a “buy” rating and set a $65.00 price target on shares of NeoGenomics in a research report on Friday, April 16th. Raymond James reaffirmed a “market perform” rating on shares of NeoGenomics in a research note on Wednesday, March 3rd. Finally, Morgan Stanley upped their price objective on shares of NeoGenomics from $46.00 to $64.00 and gave the company an “overweight” rating in a research note on Thursday, February 25th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and ten have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $50.46.
About NeoGenomics
NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates in two segments, Clinical Services and Pharma Services. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains.
Featured Story: What is a growth and income fund?
Receive News & Ratings for NeoGenomics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for NeoGenomics and related companies with MarketBeat.com’s FREE daily email newsletter.
Original Source